EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ocular Troxipide Nanosuspension Enhances Therapeutic Efficacy in an N-Acetylcysteine-Induced Dry Eye Model

Hiroko Otake, Rie Tanaka, Fumihiko Ogata iD, Yosuke Nakazawa iD, Manju Misra, Kazutaka Kanai iD, Masanobu Tsubaki iD, Naoki Yamamoto iD, Naohito Kawasaki iD, Noriaki Nagai iD

Pharmaceutics · 06.06.2026 · 18 (6) · 699

DOI: 10.3390/pharmaceutics18060699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.06.2026. Verfasst von Hiroko Otake und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by tear film instability and decreased tear secretion, largely driven by chronic ocular surface inflammation. Although current therapies primarily target inflammation and tear film stabilization, their clinical efficacy is often limited by insufficient ocular surface retention. In this study, we explored a drug repositioning strategy for DED by developing a nanocrystalline formulation of troxipide (TRO), a gastric mucosal protective agent with cytoprotective properties. Methods and Results: A TRO nanosuspension (TRO-NPs) was successfully prepared by wet bead milling, yielding particles with a mean diameter of approximately 100 nm. Physicochemical characterization revealed that the crystalline structure, solubility, viscosity, pH, and osmolarity of the nanosuspension were comparable with those of the conventional TRO microsuspension (TRO-MPs). In contrast, the TRO-NPs exhibited markedly improved dispersion stability, maintaining particle suspension for at least 1 month after preparation. Repeated topical instillation of the TRO-NPs did not induce corneal toxicity or inflammation in rabbits, and resulted in significantly higher drug retention in the tear fluid than that observed for the TRO-MPs. Furthermore, in an N-acetylcysteine-induced rabbit dry eye model, repetitive instillation of the TRO-NPs significantly increased tear volume and mucin levels, leading to improved tear film stability. Conclusions: These findings demonstrate that nanosuspension-based formulations can enhance ocular surface retention and therapeutic efficacy of TRO. TRO-NPs therefore represent a promising nanomedicine-based repositioned therapy for the treatment of DED.

Schlagwörter

Stichwörter der Autor:innen

dry eyenanosuspensionocular drug deliverytear fluidtroxipide

Autor:innen und Institutionen

  • Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan.
  • Faculty of Pharmaceutical Sciences, Doshisha Woman's College of Liberal Arts, 97-1, Minamihokotate, Kodo, Kyotanabe 610-0395, Kyoto, Japan.
  • Department of Pharmaceutics and Pharmacy Technology, L. M. College of Pharmacy, Navrangpura, Ahmedabad 380009, Gujarat, India.
  • Department of Small Animal Internal Medicine II, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23 Ban-Cho, Towada 034-8628, Aomori, Japan.
  • Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, 1314-1 Shido, Sanuki 769-2193, Kagawa, Japan.
  • University Startup Promotion Center, Research Promotion Headquarters, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan.

ORCID-Profile: Fumihiko Ogata, Yosuke Nakazawa, Kazutaka Kanai, Masanobu Tsubaki, Naoki Yamamoto, Naohito Kawasaki, Noriaki Nagai

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Otake, H., Tanaka, R., Ogata, F., Nakazawa, Y., Misra, M., Kanai, K., Tsubaki, M., Yamamoto, N., Kawasaki, N., & Nagai, N. (2026). Ocular Troxipide Nanosuspension Enhances Therapeutic Efficacy in an N-Acetylcysteine-Induced Dry Eye Model. Pharmaceutics, 18(6), 699. https://doi.org/10.3390/pharmaceutics18060699

Vancouver

Otake H, Tanaka R, Ogata F, Nakazawa Y, Misra M, Kanai K, et al. Ocular Troxipide Nanosuspension Enhances Therapeutic Efficacy in an N-Acetylcysteine-Induced Dry Eye Model. Pharmaceutics. 2026;18(6):699. doi:10.3390/pharmaceutics18060699

BibTeX
@article{Otake2026,
  author = {Otake, Hiroko and Tanaka, Rie and Ogata, Fumihiko and Nakazawa, Yosuke and Misra, Manju and Kanai, Kazutaka and Tsubaki, Masanobu and Yamamoto, Naoki and Kawasaki, Naohito and Nagai, Noriaki},
  title = {Ocular Troxipide Nanosuspension Enhances Therapeutic Efficacy in an N-Acetylcysteine-Induced Dry Eye Model},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {699},
  doi = {10.3390/pharmaceutics18060699}
}
Kostenlos starten →